通过蛋白酶靶向嵌合体（PROTAC）对CDK9进行化学诱导降解
Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC).
作者信息
Robb Caroline M, Contreras Jacob I, Kour Smit, Taylor Margaret A, Abid Mohammad, Sonawane Yogesh A, Zahid Muhammad, Murry Daryl J, Natarajan Amarnath, Rana Sandeep
机构信息
Eppley Institute for Research in Cancer and Allied Diseases, Omaha, Nebraska 68022, USA.
出版信息
Chem Commun (Camb). 2017 Jul 4;53(54):7577-7580. doi: 10.1039/c7cc03879h.
Abstract
Cyclin-dependent kinase 9 (CDK9), a member of the cyclin-dependent protein kinase (CDK) family, is involved in transcriptional elongation of several target genes. CDK9 is ubiquitously expressed and has been shown to contribute to a variety of malignancies such as pancreatic, prostate and breast cancers. Here we report the development of a heterobifunctional small molecule proteolysis targeting chimera (PROTAC) capable of cereblon (CRBN) mediated proteasomal degradation of CDK9. In HCT116 cells, it selectively degrades CDK9 while sparing other CDK family members. This is the first example of a PROTAC that selectively degrades CDK9.
摘要
细胞周期蛋白依赖性激酶9（CDK9）是细胞周期蛋白依赖性蛋白激酶（CDK）家族的成员之一，参与多个靶基因的转录延伸。CDK9在全身广泛表达，并且已被证明与多种恶性肿瘤有关，如胰腺癌、前列腺癌和乳腺癌。在此，我们报告了一种异双功能小分子蛋白酶靶向嵌合体（PROTAC）的研发情况，该嵌合体能够通过脑啡肽（CRBN）介导蛋白酶体降解CDK9。在HCT116细胞中，它能选择性地降解CDK9，而不影响其他CDK家族成员。这是选择性降解CDK9的PROTAC的首个实例。
相似文献
1
Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC).通过蛋白酶靶向嵌合体（PROTAC）对CDK9进行化学诱导降解
Chem Commun (Camb). 2017 Jul 4;53(54):7577-7580. doi: 10.1039/c7cc03879h.
2
Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.基于氨基吡唑的 CDK9 PROTAC 使胰腺癌细胞对 venetoclax 敏感。
Bioorg Med Chem Lett. 2021 Jul 1;43:128061. doi: 10.1016/j.bmcl.2021.128061. Epub 2021 Apr 23.
3
Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity.基于白杨素的 CDK9 PROTACs 的发现及其抗肿瘤活性。
Bioorg Chem. 2018 Dec;81:373-381. doi: 10.1016/j.bioorg.2018.08.028. Epub 2018 Aug 30.
4
Development of selective mono or dual PROTAC degrader probe of CDK isoforms.开发针对 CDK 同工型的选择性单或双 PROTAC 降解探针。
Eur J Med Chem. 2020 Feb 1;187:111952. doi: 10.1016/j.ejmech.2019.111952. Epub 2019 Dec 6.
5
Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer.发现小分子降解物，可靶向降解 CDK9-Cyclin T1 复合物，从而抑制前列腺癌细胞中的转录成瘾。
J Med Chem. 2022 Aug 25;65(16):11034-11057. doi: 10.1021/acs.jmedchem.2c00257. Epub 2022 Aug 4.
6
Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals).基于 Sirtuin 重排配体（SirReals）的蛋白水解靶向嵌合体（PROTAC）诱导 Sirtuin 2（Sirt2）化学降解。
J Med Chem. 2018 Jan 25;61(2):482-491. doi: 10.1021/acs.jmedchem.6b01872. Epub 2017 Apr 17.
7
Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion.通过蛋白水解靶向嵌合体（PROTAC）转化发现具有增强抗增殖活性的选择性 CDK9 降解剂。
Eur J Med Chem. 2021 Feb 5;211:113091. doi: 10.1016/j.ejmech.2020.113091. Epub 2020 Dec 10.
8
Selective CDK9 degradation using a proteolysis-targeting chimera (PROTAC) strategy.使用蛋白酶靶向嵌合体（PROTAC）策略进行选择性CDK9降解。
Future Med Chem. 2022 Jan;14(3):131-134. doi: 10.4155/fmc-2021-0220. Epub 2021 Nov 24.
9
First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo.首个口服生物可利用的蛋白水解靶向嵌合体（PROTAC）前药在体内降解细胞周期蛋白依赖性激酶 2/4/6。
Eur J Med Chem. 2021 Jan 1;209:112903. doi: 10.1016/j.ejmech.2020.112903. Epub 2020 Oct 9.
10
Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments.在肿瘤治疗中靶向 CDK9 的选择性抑制剂或降解剂：最新进展概述。
Cancer Biol Ther. 2023 Dec 31;24(1):2219470. doi: 10.1080/15384047.2023.2219470.
引用本文的文献
1
Exploiting targeted degradation of cyclins and cyclin-dependent kinases for cancer therapeutics: a review.利用细胞周期蛋白和细胞周期蛋白依赖性激酶的靶向降解进行癌症治疗：综述
J Zhejiang Univ Sci B. 2025 Aug 25;26(8):713-739. doi: 10.1631/jzus.B2500021.
2
Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs.基于 Cereblon 的 PROTAC 的合成、生物学评价及临床试验
Commun Chem. 2025 Jul 29;8(1):218. doi: 10.1038/s42004-025-01598-9.
3
Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues.癌症治疗中靶向细胞周期蛋白依赖性激酶：蛋白水解靶向嵌合体和分子胶的进展
NPJ Precis Oncol. 2025 Jun 28;9(1):204. doi: 10.1038/s41698-025-00931-8.
4
Advancing Design Strategy of PROTACs for Cancer Therapy.用于癌症治疗的PROTACs的先进设计策略
MedComm (2020). 2025 Jun 25;6(7):e70258. doi: 10.1002/mco2.70258. eCollection 2025 Jul.
5
Prodrug Strategy for PROTACs: High Efficiency and Low Toxicity.PROTACs的前药策略：高效与低毒
ACS Omega. 2025 Jun 5;10(23):23926-23942. doi: 10.1021/acsomega.5c01241. eCollection 2025 Jun 17.
6
First ATG101-recruiting small molecule degrader for selective CDK9 degradation autophagy-lysosome pathway.首个用于选择性降解CDK9的ATG101招募型小分子降解剂 自噬-溶酶体途径
Acta Pharm Sin B. 2025 May;15(5):2612-2624. doi: 10.1016/j.apsb.2025.03.047. Epub 2025 Apr 4.
7
Fluorescence based live cell imaging identifies exon 14 skipped hepatocyte growth factor receptor (MET) degraders.基于荧光的活细胞成像技术鉴定出导致14号外显子跳跃的肝细胞生长因子受体（MET）降解剂。
RSC Adv. 2025 Apr 3;15(13):10419-10425. doi: 10.1039/d5ra01441g. eCollection 2025 Mar 28.
8
Targeted degradation of CDK9 potently disrupts the MYC-regulated network.CDK9的靶向降解有力地破坏了MYC调控的网络。
Cell Chem Biol. 2025 Apr 17;32(4):542-555.e10. doi: 10.1016/j.chembiol.2025.03.001. Epub 2025 Mar 27.
9
CTDP1 and RPB7 stabilize Pol II and permit reinitiation.CTDP1和RPB7可稳定RNA聚合酶II并允许重新起始。
Nat Commun. 2025 Mar 4;16(1):2161. doi: 10.1038/s41467-025-57513-2.
10
Allostery in Disease: Anticancer Drugs, Pockets, and the Tumor Heterogeneity Challenge.疾病中的变构作用：抗癌药物、靶点口袋与肿瘤异质性挑战
J Mol Biol. 2025 Feb 26:169050. doi: 10.1016/j.jmb.2025.169050.
本文引用的文献
1
Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals).基于 Sirtuin 重排配体（SirReals）的蛋白水解靶向嵌合体（PROTAC）诱导 Sirtuin 2（Sirt2）化学降解。
J Med Chem. 2018 Jan 25;61(2):482-491. doi: 10.1021/acs.jmedchem.6b01872. Epub 2017 Apr 17.
2
A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation.一种用于诱导蛋白质降解的双特异性分子快速合成的“点击化学平台”。
J Med Chem. 2018 Jan 25;61(2):453-461. doi: 10.1021/acs.jmedchem.6b01781. Epub 2017 Apr 17.
3
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.发现一种小分子 BET 蛋白降解剂，具有皮摩尔级细胞效力，能够实现肿瘤消退。
J Med Chem. 2018 Jan 25;61(2):462-481. doi: 10.1021/acs.jmedchem.6b01816. Epub 2017 Mar 24.
4
Waste disposal-An attractive strategy for cancer therapy.废物处理——癌症治疗的一种有吸引力的策略。
Science. 2017 Mar 17;355(6330):1163-1167. doi: 10.1126/science.aam7340. Epub 2017 Mar 16.
5
Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy.蛋白酶靶向嵌合体：诱导蛋白质降解作为一种治疗策略。
ACS Chem Biol. 2017 Apr 21;12(4):892-898. doi: 10.1021/acschembio.6b01068. Epub 2017 Mar 20.
6
Targeted protein degradation by PROTACs.通过 PROTACs 进行靶向蛋白降解。
Pharmacol Ther. 2017 Jun;174:138-144. doi: 10.1016/j.pharmthera.2017.02.027. Epub 2017 Feb 14.
7
Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer.三阴性乳腺癌中BET蛋白的靶向降解
Cancer Res. 2017 May 1;77(9):2476-2487. doi: 10.1158/0008-5472.CAN-16-2622. Epub 2017 Feb 16.
8
Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras.通过靶向嵌合体蛋白酶的细胞内自组装实现蛋白质降解
ACS Cent Sci. 2016 Dec 28;2(12):927-934. doi: 10.1021/acscentsci.6b00280. Epub 2016 Dec 5.
9
Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.新型BET蛋白靶向蛋白水解嵌合体对骨髓增殖性肿瘤继发（s）急性髓系白血病细胞的致死活性优于溴结构域抑制剂（BETi）。
Leukemia. 2017 Sep;31(9):1951-1961. doi: 10.1038/leu.2016.393. Epub 2017 Feb 2.
10
Induced protein degradation: an emerging drug discovery paradigm.诱导蛋白降解：一种新兴的药物发现模式。
Nat Rev Drug Discov. 2017 Feb;16(2):101-114. doi: 10.1038/nrd.2016.211. Epub 2016 Nov 25.
Zotero 插件